Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
BACKGROUND
The efficacy and safety of sarpogrelate, a selective 5-hydroxytryptamine receptor subtype 2A antagonist, have not yet been established in bare metal coronary stenting. Accordingly, we sought to clarify whether treatment with sarpogrelate is clinically useful in bare metal coronary stenting.


METHODS
A total of 450 patients who underwent successfully planned or unplanned bare metal coronary stenting were randomly divided into the following 2 groups: the sarpogrelate (300 mg/day) plus aspirin (100 mg/day) group (group S, n=225) and the ticlopidine (200 mg/day) plus aspirin (100 mg/day) group (group T, n=225). Either sarpogrelate or ticlopidine was administered for at least 4 weeks after the procedure. Follow-up coronary arteriography was performed at 6 months after the procedure. The primary endpoints were the incidence of adverse drug reactions requiring a withdrawal of treatment and the rate of binary restenosis. The secondary endpoint was the incidence of stent thrombosis.


RESULTS
The incidence of adverse drug reactions requiring a withdrawal of treatment was significantly lower in group S than in group T (0.44% vs 8%, p=0.002). The rate of binary restenosis did not differ significantly between groups S and T (16.9% vs 18.2%). In addition, the incidence of subacute stent thrombosis did not differ between groups S and T (0.44% vs 0.44%).


CONCLUSIONS
The incidence of adverse drug reactions requiring a withdrawal of treatment was significantly lower with sarpogrelate use than with ticlopidine use. The rate of binary restenosis and the incidence of subacute stent thrombosis did not differ between both drug groups.
Tamura
Akira
A
Second Department of Internal Medicine, Oita University, Idaigaoka 1-1, Hasama-machi, Yufu, Oita 879-5593, Japan. akira@med.oita-u.ac.jp
Watanabe
Toru
T
Shinozaki
Kazuhiro
K
Kotoku
Munenori
M
Yano
Shoji
S
Kadota
Junichi
J
D000368:Aged; D023903:Coronary Restenosis / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D003328:Coronary Thrombosis / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008670:Metals / Q000009:adverse effects*; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects* / Q000145:classification*; D013386:Succinates / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects*
D008670:Metals; D013386:Succinates; C064294:sarpogrelate; D013988:Ticlopidine